{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T10:29:08Z","timestamp":1758450548022,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.metabol.2012.08.025","type":"journal-article","created":{"date-parts":[[2012,9,20]],"date-time":"2012-09-20T18:30:35Z","timestamp":1348165835000},"page":"S27-S29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S1","title":["Personalized medicine strategies for managing patients with Parkinsonism and cognitive deficits"],"prefix":"10.1016","volume":"62","author":[{"given":"Richard J.","family":"Wurtman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2012.08.025_bb0005","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/archneur.1992.00530290076015","article-title":"A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender","volume":"49","author":"Mayeux","year":"1992","journal-title":"Arch Neurol"},{"key":"10.1016\/j.metabol.2012.08.025_bb0010","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/01.wnl.0000180516.69442.95","article-title":"Cognitive profile of patients with newly diagnosed Parkinson disease","volume":"65","author":"Muslimovic","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.metabol.2012.08.025_bb0015","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1212\/01.wnl.0000256715.13907.d3","article-title":"DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers","volume":"68","author":"Lippa","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.metabol.2012.08.025_bb0020","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/jnnp.2004.052332","article-title":"The role of levodopa in the management of dementia with Lewy bodies","volume":"76","author":"Molloy","year":"2005","journal-title":"J Neurol Neurosury Psychiatry"},{"key":"10.1016\/j.metabol.2012.08.025_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1474-4422(03)00619-7","article-title":"Dementia with Lewy bodies","volume":"3","author":"McKeith","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.metabol.2012.08.025_bb0030","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/jnnp.2006.093146","article-title":"Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease","volume":"77","author":"Bronnick","year":"2006","journal-title":"J Neuro Neurosurg Psychiatry"},{"key":"10.1016\/j.metabol.2012.08.025_bb0035","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.metabol.2012.08.025_bb0040","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.metabol.2012.08.025_bb0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of Florbetapir-PET for imaging \u03b2-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2012.08.025_bb0050","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1523\/JNEUROSCI.4564-06.2007","article-title":"Presdynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies","volume":"27","author":"Kramer","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.metabol.2012.08.025_bb0055","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-beta protein dimmers isolated directly from Alzheimer's brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2012.08.025_bb0060","first-page":"4012","article-title":"Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques","volume":"1","author":"Koffie","year":"2007","journal-title":"PNAS"},{"key":"10.1016\/j.metabol.2012.08.025_bb0065","first-page":"70","article-title":"Nervous system pathology I sporadic Parkinson's disease","volume":"2008","author":"Braak","year":"1916","journal-title":"Neurology"},{"key":"10.1016\/j.metabol.2012.08.025_bb0070","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrn1199","article-title":"The role of alpha-synuclein in Parkinson's disease: insights from animal models","volume":"4","author":"Maries","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.metabol.2012.08.025_bb0075","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1212\/01.wnl.0000271880.27321.a7","article-title":"Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder","volume":"69","author":"Klein","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.metabol.2012.08.025_bb0080","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/archneur.63.9.1232","article-title":"Genetic testing in Parkinson disease: promises and pitfalls","volume":"63","author":"Tan","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.metabol.2012.08.025_bb0085","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/jnnp.2008.151654","article-title":"Twin pairs discordant for neuropathologically confirmed Lewy body dementia","volume":"80","author":"Wang","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.metabol.2012.08.025_bb0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ana.22155","article-title":"The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial","volume":"69","author":"Corvol","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.metabol.2012.08.025_bb0095","first-page":"82","article-title":"Recent imaging advances in the diagnosis and management of Parkinson's disease","volume":"1","author":"Brooks","year":"2009","journal-title":"F1000 Rep"},{"key":"10.1016\/j.metabol.2012.08.025_bb0100","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1093\/brain\/awg204","article-title":"Frontotemporal dementia in the Netherlands: patient characteristics and prevalence estimates from a population-based study","volume":"126","author":"Rosso","year":"2003","journal-title":"Brain"},{"issue":"14","key":"10.1016\/j.metabol.2012.08.025_bb0105","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/mds.22690","article-title":"A longitudinal program for biomarker development in Parkinson's disease: a feasibility study","volume":"24","author":"Ravina","year":"2009","journal-title":"Mov Disord"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049512003290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049512003290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:58:21Z","timestamp":1758427101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049512003290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":21,"alternative-id":["S0026049512003290"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2012.08.025","relation":{},"ISSN":["0026-0495"],"issn-type":[{"type":"print","value":"0026-0495"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized medicine strategies for managing patients with Parkinsonism and cognitive deficits","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2012.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}